ArticleCancers2026
Deep Learning-Based Computer-Aided Detection and Diagnosis System for Malignant Biliary Stricture (With Video).
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND/
objectivesMalignant biliary stricture (MBS) remains difficult to diagnose accurately despite digital single-operator cholangioscopy (DSOC). We developed a deep learning (DL)-based computer-aided detection (CADe) and diagnosis (CADx) system for DSOC-based MBS assessment.
methodsThis retrospective multicenter study included 149 patients from one center for model development and internal validation and 25 patients from two independent centers for external evaluation. CADe used a You Only Look Once version 11 (YOLOv11) architecture to localize irregular mucosa, abnormal vasculature, and nodular protrusions defined by the Carlos Robles-Medranda and Mendoza criteria. CADx used a Residual Network-18 classifier with gradient-weighted class activation mapping for interpretability.
resultsCADe achieved a mean average precision at 50% intersection-over-union of 91.2%, with a precision of 92.0% and recall of 87.0%. CADx achieved a frame-level area under the receiver operating characteristic curve (AUC) of 0.960 in internal validation and 0.843 in external validation. External frame-level sensitivity was 52.0% and specificity was 95.2%. For the patient-level external endpoint, sensitivity was 85.7%, specificity was 94.4%, accuracy was 92.0%, and AUC was 0.881.
conclusionsThe two-stage system combines localization of predefined cholangioscopic features with interpretable diagnostic classification. The small external cohort and marked reduction in frame-level sensitivity preclude firm conclusions regarding generalizability; prospective multicenter and live-procedure evaluation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.